© Wiley Periodicals, Inc.
Edited By: Henrique von Gersdorff
Impact Factor: 2.127
ISI Journal Citation Reports © Ranking: 2014: 170/252 (Neurosciences)
Online ISSN: 1098-2396
Recently Published Issues
The articles below have been specially selected by our editors to highlight to the Synapse community. Read more
Characterization of the novel GlyT1 PET tracer [18F]MK-6577 in humans
Aniket D. Joshi, Sandra M. Sanabria-Bohórquez, Guy Bormans, Michel Koole, Jan De Hoon, Anne Van Hecken, Marleen Depre, Inge De Lepeleire, Koen Van Laere, Cyrille Sur and Terence G. Hamill
Dose-dependent, saturable occupancy of the metabotropic glutamate subtype 5 receptor by fenobam as measured with [11C]ABP688 PET imaging
William B. Mathews, Hiroto Kuwabara, Kirstie Stansfield, Heather Valentine, Mohab Alexander, Anil Kumar, John Hilton, Robert F. Dannals, Dean F. Wong and Fabrizio Gasparini
Adolescent bisphenol-A exposure decreases dendritic spine density: Role of sex and age
Rachel E. Bowman, Victoria Luine, Hameda Khandaker, Joseph J. Villafane and Maya Frankfurt
Prefrontal cortex, hippocampus, and basolateral amygdala plasticity in a rat model of autism spectrum
Nuvia Sosa-Díaz, Maria Elena Bringas, Marco Atzori and Gonzalo Flores
News & Special Features
Synapse is pleased to welcome Erwan Bezard and Benjamin Hall as new Associate Editors
Benjamin Hall is a Principal Scientist at F. Hoffman-La Roche Ltd., working at the Roche Innovation Center Basel, Switzerland. He also holds an Adjunct Professorship in the Cell and Molecular Biology Department and Neuroscience Program at Tulane University in New Orleans, Louisiana. His research investigates the role of NMDA receptors and late-stage transcription factors in the regulation of synaptic function in the cortex with a focus on synapse development and cortical circuit formation in relation to neurodevelopmental disorders. Recent work from his lab is also focused on understanding the cellular mechanisms that initiate the antidepressant actions of low-dose ketamine. He is a National Science Foundation CAREER award recipient, a two-time recipient of the Brain and Behavior Foundation’s NARSAD Young Investigator award, a Grass Foundation Fellow, and previous Staglin Music Festival Investigator.
Erwan Bezard is the Director of the Institute of Neurodegenerative Diseases at University of Bordeaux, which features preclinical and clinical researchers working towards development of therapeutic solutions. He has authored or co-authored over 198 professional publications, most of which are on Parkinson's disease and related disorders. Listed in the Top 1% of the most cited neuroscientists, he is known for his work (i) on the compensatory mechanisms that mask the progression of Parkinson's disease, (ii) on the pathophysiology of levodopa-induced dyskinesia and (iii) on the mechanisms of neurodegeneration in synucleopathies. His current research interests include the study of the levodopa-induced dyskinesia, the intimate mechanisms of cell death in Parkinson’s disease, the modelling of disease progression and the development of new strategies to alleviate symptoms and/or to slow disease progression.